ADHD guidelines for Australian general practitioners - clinical fact sheet and MCQ
Overview
The Australian Clinical Practice Guideline for ADHD provides evidence-based recommendations for diagnosing, managing, and supporting individuals with ADHD, tailored to the Australian context. Developed by the Australasian ADHD Professionals Association (AADPA), the guideline emphasises person-centred, multidisciplinary approaches to improve quality of life for the over one million Australians affected.
Identification and diagnosis of ADHD
Universal screening for ADHD is not recommended. However, clinicians should remain vigilant for ADHD in populations with a high prevalence which include individuals with a history of ADHD in immediate relatives, those with neurodevelopmental conditions, or those in correctional facilities (see Guideline for full list).
It is important to be aware that ADHD is often under-recognised in females.
Diagnosis requires a comprehensive assessment, incorporating clinical and psychosocial assessment, developmental and medical history, observer reports, and the use of validated criteria (DSM-5, ICD-10/11) by an appropriately trained clinician. Comorbid conditions, such as anxiety or substance use disorders, should be carefully evaluated.
Treatment of ADHD
A multimodal treatment approach is advised:
-
Non-pharmacological interventions:
-
parent/family training: to equip parents/carers with the specific skills required to meet the additional needs of children and adolescents with ADHD
-
cognitive-behavioural interventions: include a variety of approaches that aim to address behavioural factors, psychological distress, and mental ill-health, rather than ADHD symptoms
-
lifestyle modifications: with a specific focus on optimising sleep, diet, and physical activity to improve day-to-day functioning
-
ADHD coaching: to improve executive functioning, symptoms, self-esteem, general wellbeing, and overall quality of life
-
Pharmacological treatment:
-
pharmacological treatment for children ≤5 should involve a clinician with experience in child development and ADHD
-
first-line medications include monotherapy with stimulants (methylphenidate, dexamfetamine, lisdexamfetamine) for children >5 years old, adolescents, and adults, where symptoms are causing significant impairment
-
non-stimulant alternatives such as atomoxetine or guanfacine may be used if stimulants are ineffective or contraindicated
-
comprehensive monitoring of medication effects include height/weight, cardiovascular function, sleep, sexual function, seizures, emotional and mental health
-
medication should be initiated and monitored by appropriately trained clinicians
Implementation
Practitioners are encouraged to adopt the guideline’s recommendations collaboratively with patients and their carers, integrating evidence, clinical judgement, and individual preferences. Consistent monitoring and adjustment of treatment plans ensure optimised outcomes.
Claim your CPD
After reading the FastTrack CPD above and reviewing the references, complete the quiz to gain 15 minutes of EA CPD and 15 minutes of RP CPD.
You can either self-report CPD to your CPD home, or Medcast will track your learning via your personal CPD Tracker and you can download and report these points once a year. See our CPD Tracker FAQ.
Quiz
Answer the following five (5) questions, and review the answers to complete this learning activity.
Related Courses
With increasing public awareness of ADHD, GPs are now at the front line of identifying and supporting management of this condition. Up to 10% of children and 5% of adults exhibit ADHD symptoms, indicating there is a heightened need for GPs to understand their role in supporting these patients.
The Medcast medical education team is a group of highly experienced, practicing GPs, health professionals and medical writers.
Become a member and get unlimited access to 100s of hours of premium education.
Learn moreMedcast Medical Education Team
Crohn’s disease (CD) is a chronic inflammatory bowel disease affecting any part of the GI tract. It has genetic and environmental triggers and presents with symptoms like abdominal pain, diarrhoea, and weight loss. Diagnosis involves endoscopy and imaging. Management includes corticosteroids, biologics, immunomodulators, lifestyle changes, and psychological support. This FastTrack-CPD provides a clinical summary on the management of Crohn's disease with a quiz to apply your learning and receive CPD (RP and EA categories).
Medcast Medical Education Team
Polycystic ovary syndrome (PCOS) affects 10–13% of women, with higher prevalence in certain ethnic groups. It is characterized by hyperandrogenism, menstrual irregularities, and polycystic ovarian morphology. PCOS increases the risk of type 2 diabetes, cardiovascular disease, and requires early diagnosis and personalized management to reduce long-term effects. This FastTrack-CPD provides a clinical summary on the management of PCOS with a quiz to apply your learning and receive CPD (RP and EA categories).
Medcast Medical Education Team
A chalazion is a painless, chronic eyelid swelling caused by a blocked meibomian gland, leading to granulomatous inflammation. It can persist for weeks to months and is more common in adults. Risk factors include blepharitis, ocular rosacea, and seborrhoeic dermatitis. This FastTrack-CPD provides a clinical summary on the management of chalazion with a quiz to apply your learning and receive CPD (RP and EA categories).